Advertisement

Related Videos

Welcome and Introduction to Vi3C

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Oct
10
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo